EGFR and colorectal cancer: As other KRAS mutants did not show the activation of EGFR and p53, these authors suggest that this activation could be the biological explanation of the favorable clinical outcome of colorectal cancer patients harboring KRAS G13D mutation treated with anti-EGFR therapy compared to patients with KRAS codon 12 mutations (6).